University of Bern
New findings in the area of oncology described
Published in Law and Health Weekly, April 8th, 2006
Study 1: The selective Cox-2 inhibitor celecoxib challenges angiogenesis and bone metastasis in tumor models.
"The inhibition of angiogenesis is a promising strategy for the treatment of malignant primary and secondary tumors in addition to established therapies such as surgery, chemotherapy, and radiation. There is strong experimental evidence in primary tumors that cyclooxygenase-2 (Cox-2) inhibition is a potent mechanism to reduce angiogenesis," scientists in Switzerland report.
"For bone metastases which occur in up to 85% of the most frequent...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- Braintree Laboratories, Inc.
Braintree Laboratories in-licenses rights to chemoprevention agent against colorectal cancer - Dana-Farber Cancer Institute, Boston
Ovarian cancer patients treated by gynecologic oncologists had better outcomes - DiagnoCure, Inc.
DiagnoCure wins U.S. patent for PCA3 - Drug Abuse
NSF International unveils new banned substances certification program for all sports - Drug Abuse
Safeway adds restrictions for pseudoephedrine product sales to curtail meth abuse - FEI Company
FEI and Sidec tackle validation of drug targets - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
